Table 5. Abbott anti-SARS-CoV-2 Architect and Alinity assays sensitivity of each assay compared with in-house ELISA.
| Abbott SARS-CoV2 Assay Architect (n = 197) | Abbott SARS-CoV2 Assay Alinity (n = 191a) | ||
|---|---|---|---|
| Sensitivity % | Cumulative sensitivity | 94.7% (95% CI: 88.8%-98%) | 92.5% (95% CI: 85.8%-96.7%) |
| 0–7 days | 13/14, 92.8% | 13/14, 92.9% | |
| 8–14 | 11/12, 91.7% | 7/8, 87.5% | |
| 15–21 | 12/14, 85.7% | 12/14, 85.7% | |
| 22–30 | 10/12, 83.3% | 10/13, 76.9% | |
| 31–40 | 12/12, 100% | 12/12, 100% | |
| 41–50 | 14/14, 100% | 14/14, 100% | |
| >51 | 32/32, 100% | 29/30, 96.6% | |
| Cumulative specificity % | 88.1% (95% CI: 79.2%-94.1%) | 91.7% (95% CI: 83.6%-96.6%) | |
aBecause of sample availability, the number of samples used for the Abbott SARS-CoV2 Alinity Assay differs from that used for the Abbott SARS-CoV2 Architect Assay.